Notice for pembrolizumab (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
pembrolizumab
Date of review outcome
Lapse date
Type
Priority review
Indication
Pembrolizumab in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumour aberrations.